<DOC>
	<DOCNO>NCT02696785</DOCNO>
	<brief_summary>The main purpose study evaluate safety efficacy study drug know ixekizumab biological disease-modifying anti-rheumatic drug ( bDMARDs ) -naive participant radiographic axial spondyloarthritis ( rad-axSpA ) .</brief_summary>
	<brief_title>A Study Ixekizumab ( LY2439821 ) bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis</brief_title>
	<detailed_description />
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Are ambulatory . Diagnosis radiographic axial spondyloarthritis ( radxSpA ) sacroiliitis define radiographically accord modify New York criterion . Participants history back pain â‰¥3 month age onset &lt; 45 year . In past inadequate response least 2 nonsteroidal antiinflammatory drug ( duration 4 week ) tolerate NSAIDS . If take NSAIDS stable dose least 2 week prior randomization . Have history prior therapy axSpa least 12 week prior screen . Have total ankylosis spine . Have receive prior , currently receive , treatment biologics , tumor necrosis factor inhibitor immunomodulatory agent . Have recently receive live vaccine within 12 week vaccination Bacillus CalmetteGuerin ( BCG ) within past year . Have ongoing serious infection within last 12 week evidence active tuberculosis . Have compromise immune system . Have serious and/or uncontrolled disease . Have either current diagnosis recent history malignant disease . Have major surgery within 8 week baseline , require surgery study . Are pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Ankylosing Spondylitis</keyword>
</DOC>